Úna C. McMenamin

Úna C. McMenamin

Auto-generated profile, based on publicly available information

Úna C. McMenamin

Queen’s University Belfast 3 Centre for Public Health Belfast, United Kingdom

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MDMichelle T Doherty
Michelle T Doherty
OSOmolara B Sanni
Omolara B Sanni
HCHelen G Coleman
Helen G Coleman
CCChris R Cardwell
Chris R Cardwell
WMW Glenn McCluggage
W Glenn McCluggage
ÚMÚna C McMenamin
Úna C McMenamin
To inform treatment decisions in women diagnosed with endometrial hyperplasia, quantification of the potential for concurrent endometrial cancer and the future risk of progression to cancer is required. We identified studies up to September 2018 that reported on the prevalence of concurrent cancer (within three months of endometrial hyperplasia diagnosis), or the incidence of cancer, identified at least three months after hyperplasia diagnosis. Random-effects meta-analyses produced pooled estimates and 95% confidence intervals (CIs). A total of 36 articles were identified; 15 investigating concurrent and 21 progression to cancer. In pooled analysis of 11 studies of atypical hyperplasia, the pooled prevalence of concurrent endometrial cancer was 32.6% (95% CI: 24.1%, 42.4%) while no studies evaluated concurrent cancer in non-atypical hyperplasia. The risk of progression to cancer was high in atypical hyperplasia (n = 5 studies, annual incidence rate = 8.2%, 95% CI 3.9%, 17.3%) and only one study reported on non-atypical hyperplasia (annual incidence rate = 2.6%, 95% CI: 0.6%, 10.6%). Overall, a third of women with atypical hyperplasia had concurrent endometrial cancer, although the number of studies, especially population-based, is small. Progression to cancer in atypical hyperplasia was high, but few studies were identified. Population-based estimates are required, in both atypical and non-atypical hyperplasia patients to better inform treatment strategies.

30 April 2015 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
CCChris R. Cardwell
Chris R. Cardwell
ÚMÚna Mc Menamin
Úna Mc Menamin
CHCarmel M. Hughes
Carmel M. Hughes
LMLiam J. Murray
Liam J. Murray
Background: Preclinical evidence from lung cancer cell lines and animal models suggest that statins could have anticancer properties. We investigated whether statin users had reduced risk of cancer-specific mortality in a population-based cohort of lung cancer patients.

3 April 2014 in Gut
Verified
Journal Article
Closed access
PDF file
SBShivaram K Bhat
Shivaram K Bhat
DMDamian T McManus
Damian T McManus
HCHelen Coleman
Helen Coleman
BJBrian T Johnston
Brian T Johnston
CCChristopher R Cardwell
Christopher R Cardwell
LMLiam J Murray
Liam J Murray
Objective Endoscopic surveillance of Barrett's oesophagus (BO) provides an opportunity to detect early stage oesophageal adenocarcinoma (OAC). We sought to determine the proportion of OAC patients with a prior diagnosis of BO on a population basis and to evaluate the influence of a prior diagnosis of BO on survival, taking into account lead and length time biases. Design A retrospective population-based study of all OAC patients in Northern Ireland between 2003 and 2008. A prior BO diagnosis was determined by linkage to the Northern Ireland BO register. Stage distribution at diagnosis and histological grade were compared between patients with and without a prior BO diagnosis. Overall survival, using Cox models, was compared between patients with and without a prior BO diagnosis. The effect of adjusting the survival differences for histological grade and estimates of lead and length time bias was assessed. Results There were 716 OAC cases, 52 (7.3%) of whom had a prior BO diagnosis. Patients with a prior BO diagnosis had significantly lower tumour stage (44.2% vs 11.1% had stage 1 or 2 disease; p<0.001), a higher rate of surgical resection (50.0% vs 25.5%; p<0.001) and had a higher proportion of low/intermediate grade tumours (46.2% vs 26.5%; p=0.011). A prior BO diagnosis was associated with significantly better survival (HR for death 0.39; 95% CI 0.27 to 0.58), which was minimally influenced by adjustment for age, sex and tumour grade (adjusted HR 0.44; 95% CI 0.30 to 0.64). Correction for lead time bias attenuated but did not abolish the survival benefit (HR 0.65; 95% CI 0.45 to 0.95) and further adjustment for length time bias had little effect. Conclusions The proportion of OAC patients with a prior diagnosis of BO is low; however, prior identification of BO is associated with an improvement in survival in OAC patients.

11 December 2017 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
ASAndrew D. Spence
Andrew D. Spence
CCChris R. Cardwell
Chris R. Cardwell
ÚMÚna C. McMenamin
Úna C. McMenamin
BHBlanaid M. Hicks
Blanaid M. Hicks
BJBrian T. Johnston
Brian T. Johnston
HCHelen Coleman
Helen Coleman
Gastric cancer (GC) has a poor prognosis with wide variation in survival rates across the world. Several studies have shown premalignant lesions gastric atrophy (GA) and intestinal metaplasia (IM) influence gastric cancer risk. This systematic review examines all available evidence of the risk of GC in patients with GA or IM and explores the geographical variation between countries. EMBASE, MEDLINE, Web of Science and the Cochrane Library were searched for relevant articles published to June 2016 investigating the risk of GC in individuals with GA or IM. Analysis was performed to determine variation based on geographical location. Study quality was assessed using the Newcastle-Ottawa Scale and heterogeneity between studies was also evaluated. Fifteen relevant articles were identified, in which there were eight studies of GC incidence in GA and nine in IM cohorts (two articles investigated both GA and IM). The incidence rate of GC in patients with GA ranged from 0.53 to 15.24 per 1000 person years, whereas there was more variation in GC incidence in patients with IM (0.38 to 17.08 per 1000 person years). The greatest GC incidence rates were in Asian countries, for patients with GA, and the USA for those with IM (15.24 and 17.08 per 1000 person years, respectively). The largest studies (four over 25,000 person years) had an incidence rate range of 1.0–2.5 per 1000 person years, however, in general, study quality was poor and there was marked heterogeneity. Overall there is a wide variation in annual incidence rate of GC from premalignant lesions. With the recent introduction of surveillance guidelines for gastric atrophy and intestinal metaplasia in the Western world, future assessment of this risk should be performed. Furthermore, substantial heterogeneity supports the need for more robust studies in order to pool results and determine the overall incidence rate of gastric cancer for patients with these premalignant lesions.

25 November 2011 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
ÚMÚna C. Mc Menamin
Úna C. Mc Menamin
LMLiam J. Murray
Liam J. Murray
MCMarie M. Cantwell
Marie M. Cantwell
CHCarmel M Hughes
Carmel M Hughes

16 August 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
CTCharlene Treanor
Charlene Treanor
UMUna C McMenamin
Una C McMenamin
RORoisin F O'NEill
Roisin F O'NEill
CCChris R Cardwell
Chris R Cardwell
MCMike J Clarke
Mike J Clarke
MDMichael Donnelly
Michael Donnelly